SAN DIEGO, September 21, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study that uses OGM to discover coding balanced chromosomal rearrangements (BCRs) found in people who have experienced recurrent pregnancy loss. (RPL). Compared with conventional cytogenetic methods, OGM was successful in identifying the reciprocal coding translocation in all samples, which improved the success rate in finding pathogenic variants of coding BCRs and simplified the discovery process.
The researchers analyzed samples from 11 couples who had treated RPL, had a history of having a baby or fetus with a chromosome loss or gain, or had a history of infertility to determine the usefulness of OGM for detecting encoded BCRs, which can significantly increase the risk of delivering abnormal offspring with Congenital malformations or miscarriages for carrier couples. The OGM showed 100% concordance with the results of fluorescence in situ hybridization (FISH) and sequencing analyzes and revealed additional complex rearrangement events such as inverted aberrations, further improving potential genetic interpretation. The study authors highlighted the challenges associated with using traditional methods and cited the rapid and robust OGM detection of high-resolution encoded BCRs as evidence for their potential application as a first-line method in routine clinical genetic testing.
Eric Holmlin, Ph.D., President and CEO of Bionano, commented, “This study demonstrates OGM support in an area that we believe may be very beneficial for people with infertility and pregnancy loss. We are pleased to see the researchers recommending OGM as an initial way to replace traditional methods, some of which have been It’s been around for 50 years.”
This post can be found here: https://jmg.bmj.com/content/early/2022/06/15/jmedgenet-2022-108553
About the Bionano . genome
Bionano Genomics is a company that provides genome analysis solutions that can enable researchers and clinicians to uncover answers to challenging questions in biology and medicine. The company’s mission is to change the way the world sees the genome through OGM solutions, diagnostic services and software. The company delivers OGM solutions for applications across basic, translational and clinical research. Through the Lineagen business, the company also provides diagnostic tests for patients with clinical presentations compatible with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the company also offers an industry-leading, platform-less software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation, and reporting of copy number variants, single nucleotide variants, and absences of heterozygosity across the genome in a single view. unified. For more information visit www.bionanogenomics.comAnd the www.lineagen.com or www.biodiscovery.com
Forward-looking statements for Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “could,” “believe,” and similar expressions (as well as other words or phrases that refer to future events, circumstances or conditions) They convey uncertainty about future events or results and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, expectations, expectations, analyzes or current expectations relating to, among other things, the ability and usefulness of the OGM to detect cryptographic BCRs. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments could differ materially from those projected or implied in these forward-looking statements. Factors that may cause this difference include risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; Changes in the competitive landscape and introduction of competitive technologies or improvements to existing technologies; The results of the prospective study fail to support those described in the paper referenced in this press release; OGM fails to detect encoded BCRs; changes in our strategic and business plans; Our ability to obtain sufficient funding to fund our strategic plans and marketing efforts; The ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including those described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2021 and in other filings which we later filed with the Securities and Exchange Commission. All forward-looking statements in this press release speak only as of the date they were made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events, or otherwise.
Eric Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243